戻る Agenda
Session 3, Track A: Reducing Burden, Accelerating Access - How Health Canada Is Streamlining Regulatory Work
Session Chair(s)
Myriam Salem
National Supervisor, Regulatory Operations and Enforcement Branch, Health Canada, Canada
Yatika Kohli, MBA
Chief Compliance and Strategy Officer, NoNO Inc, Canada
This session highlights Health Canada’s ongoing efforts to reduce regulatory burden, strengthen collaboration, and accelerate access to innovative therapies. Through three focused presentations, Health Canada will outline its latest red tape reduction initiatives designed to streamline processes and improve regulatory efficiency; provide an update on data sharing initiative that supports smarter, more connected regulatory decision making; and share insights on oncology drug approvals under the NOC/c pathway, including how evidence generation, international reliance, and regulatory agility are being leveraged to bring promising cancer therapies to patients sooner. Together, these presentations offer a comprehensive view of how Health Canada is modernizing its regulatory approach to deliver faster, more predictable, and more efficient outcomes for patients and industry.
HC’s Business Facilitation and Modernization Directorate and its Role in AI
Seema Verma-Pharasi, Health Canada
From Red Tape Reduction to Real-World Impact: Accelerating Access to Medicines Through Regulatory Modernization
Jeffrey Skene, Health Canada
Early Access, Proven Impact: A Retrospective Analysis of Oncology Drug Approvals Under Health Canada’s Notice of Compliance with Conditions (NOC/c) Policy
Oncology Drug Approvals Under Health Canada’s Notice of Compliance With Conditions Policy: A Retrospective Cohort Analysis
Jan Brun, Health Canada
Speaker(s)
From Red Tape Reduction to Real-World Impact: Accelerating Access to Medicines Through Regulatory Modernization
Jeffrey Skene, MS
Executive Director, Bureau of Cardiology, Allergy and Neurological Science, Health Canada, Canada
Early Access, Proven Impact: A Retrospective Analysis of Oncology Drug Approvals Under Health Canada’s Notice of Compliance with Conditions (NOC/c) Policy
Jan Brun, PhD
Senior Clinical Oncology Reviewer, Health Canada, Canada
HC’s Business Facilitation and Modernization Directorate and its Role in AI
Seema Verma-Pharasi, MSc
Executive Director, Regulatory Enablement Services (RES), Health Canada, Canada